The Gray Laboratory explores mechanisms by which genomic, transcriptional and proteomic abnormalities occur in selected cancers. Current studies focus on developing: (a) integrated analyses of the spectrum of recurrent abnormalities that influence cancer behavior, (b) mathematical models that describe how cancer-associated molecular abnormalities influence individual responses to therapeutic inhibitors, (c) novel therapeutic approaches to treat cancer subpopulations that do not respond well to current aggressive chemotherapeutic strategies, (d) automated functional assessment of genes deregulated by genomic abnormalities in cancers, (e) molecular imaging for early detection of metastasis prone breast cancer, and (f) spatial systems biomedicine. Research in these areas is typically multi-institutional and multi-disciplinary.